IL-6受体及其受体抗体在Graves眼病中的作用研究进展

Update of interleukin-6 receptor and its antibody′s role in Graves′orbitopathy

Graves眼病(Graves′orbitopathy,GO)是Graves病(Graves′disease,GD)的主要甲状腺外表现。中度至重度GO是治疗的主要挑战,因其通常对现有的药物治疗反应不完全。糖皮质激素是中重度活动性GO的一线治疗方案,但有不少GO患者存在糖皮质激素治疗抵抗。研究已表明,白细胞介素(IL)-6受体参与了GO的发展。作为一种直接针对IL-6的重组人源化单克隆抗体,托珠单抗在临床研究中被证实对中到重度糖皮质激素抵抗的GO患者确有疗效,这表明靶向阻断IL-6受体的药物未来可能在GO治疗中占有一席之地。

Graves′orbitopathy(GO)is the main extrathyroidal manifestation of Graves′disease(GD).GO is a major therapeutic challenge in its moderate-to-severe forms,often incompletely responsive to available medical treatments.Glucocorticoids are the first-line treatment for moderate to severe active Graves′orbitopathy(GO),but a certain amount of GO patients are still refractory to glucocorticoids treatment.Previous research have found that IL-6R participates in the development of GO.As a recombinant humanized monoclonal antibody directed against the IL-6 receptor,TCZ has shown its efficacy in moderate to severe glucocorticoid resistant GO patients.Therefore,drugs targeting IL-6R may claim its place in GO treatment someday.